News

Autism’s Molecular Mechanisms Uncovered through Protein-Protein Interaction Network

This week, Nevan Krogan’s group posted a preprint describing a PPI network involving 100 ASD risk genes.

MindRhythm Completes Enrollment in its Multicenter Prehospital Trial for Identifying Large Vessel Occlusion Stroke

MindRhythm's EPISODE trial, the largest study of a prehospital stroke device in existence, has stopped enrolling new patients, has been closing down the sites, and is beginning to unblind the data for analysis. This is a very exciting milestone! Shortly they will reveal the results of the trial...

KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy

KSQ Therapeutics, a clinical-stage biotechnology company developing novel treatments for solid tumors, in collaboration with The University of Texas MD Anderson Cancer Center and the Cell Therapy Manufacturing Center (CTMC), today announced the Food and Drug Administration (FDA) has cleared an...

AskBio Announces First Patient Randomized in Phase 1 Trial of Gene Therapy for Multiple System Atrophy-Parkinsonian

“Enrolling the first patient in our REGENERATE MSA-101 trial is an important step in AskBio’s ongoing work to advance GDNF gene therapy,” said Krystof Bankiewicz, MD, PhD, Scientific Chair, Parkinson’s and MSA, AskBio. “The clinical advancement of AB-1005 for the treatment of MSA-P comes as we are...

Autobahn Labs Announces Key Licensing Milestones in Alliances with Early University Partners

Autobahn Labs, an early-stage drug discovery incubator, announced today that it had executed exclusive license agreements to foundational technologies in its collaborations with the Los Angeles and San Francisco campuses of the University of California. The objective of Autobahn’s collaborations...

AbbVie Exercises Exclusive Right to Acquire Mitokinin

Mitokinin, a UCSF startup founded on work developed in Dr. Kevan Shokat’s lab, has been acquired by AbbVie Pharmaceuticals for $110 million. The foundational technology developed by UCSF inventors activates PINK1 to remediate mitochondrial damage, a key driver in the pathogenesis of Parkinson’s...

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis

Phase 1 trial to investigate multiple B-cell mediated autoimmune diseases First healthy donor-derived allogeneic CAR T cell therapy to announce IND clearance Expect to disclose initial clinical data next year.

Balancing Startup Risk and Reward

On November 1st, the UCSF Innovation Ventures' Engagement and Opportunity Development Team and Mubadala Capital's Healthcare Ventures team co-hosted an Investor and Founder Panel Discussion on Balancing Startup Risk and Reward.

Siren Biotechnology Awarded $4M in Grant Funding from the California Institute for Regenerative Medicine (CIRM)

Siren Biotechnology, a gene therapy company pioneering Universal AAV Immuno-Gene Therapies for Cancer™, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $4M translational research grant to support the development of novel AAV immuno-gene...

AbbVie Exercises Exclusive Right to Acquire Mitokinin

AbbVie announced today that it has exercised its exclusive right and completed the acquisition of Mitokinin, a discovery-stage biotechnology company developing a potentially first-in-class disease-modifying treatment for Parkinson's Disease (PD). Mitokinin's lead compound, a selective PINK1...